Mast Cell Activation Syndrome
A multi-system inflammatory condition commonly misattributed to anxiety or allergy — and central to the hypermobility-dysautonomia-MCAS triad we see in a substantial fraction of complex cases.
What we mean when we say MCAS.
MCAS is a disorder of inappropriate mast cell activation: immune cells releasing histamine, tryptase, leukotrienes, prostaglandins, and other mediators without an appropriate allergic trigger. The result is a multi-system symptom picture spanning cutaneous, gastrointestinal, cardiovascular, neurologic, and respiratory domains.
MCAS frequently co-occurs with POTS and hypermobile EDS — a triad often described in current literature as a syndromic hub rather than three separate conditions. Overlap with SIBO, gastroparesis, and autoimmune features is common, and the integrated picture changes treatment strategy materially.
The condition predominantly affects women, onset most often in the 30s–50s, with median diagnostic delays of many years. Patients are routinely routed to allergy, psychiatry, or GI — rarely to the smaller set of clinicians who recognize the syndrome as its own entity.
The pattern we see in MCAS cases.
- 01No universal diagnostic consensus. Major frameworks — Afrin/Molderings consensus II, the Akin/Valent proposal, and regional variants — differ on criteria, biomarkers, and treatment thresholds. Which framework your clinician uses changes whether you have a diagnosis.
- 02Laboratory markers (serum tryptase, urinary mediator metabolites) are often normal, and require specific timing, sample handling, and clinical context to be interpretable. A normal test does not rule out MCAS.
- 03Treatment is step-wise and highly individual — H1 and H2 blockers, mast-cell stabilizers, leukotriene modulators, low-dose naltrexone, and trigger management each have a role in different cases.
- 04Most allergists and immunologists outside academic centers are unfamiliar with MCAS as distinct from systemic mastocytosis. Patients are frequently told they're fine or dismissed to psychiatry before reaching an MCAS-aware clinician.
The Ternary Signal Library for MCAS.
Our Signal Library codifies the specific patterns that matter in MCAS — labs, genetic variants, imaging findings, symptom clusters, and comorbidity combinations. Your case is mapped against these signals in Stage 4 of the workflow; each activated signal is weighted and prioritized for your presentation.
- —Cutaneous — flushing, urticaria, pruritus, dermographism
- —GI — diarrhea, reflux, abdominal pain, food intolerances
- —Cardiovascular — tachycardia episodes, hypotension, syncope
- —Neurologic — brain fog, headache, paresthesia
- —Respiratory — nasal congestion, wheeze, dyspnea
- —Episodic pattern — trigger, severity, duration mapping
- —Serum tryptase — baseline and timed post-episode
- —Urinary N-methylhistamine, prostaglandin D2 metabolites
- —Urinary leukotriene E4
- —CBC with differential (eosinophils, basophils)
- —Total IgE and specific IgE panels
- —Chromogranin A
- —Food triggers — high-histamine, high-tyramine, salicylate
- —Chemical / fragrance / environmental triggers
- —Temperature, exercise, stress triggers
- —Medication sensitivities
- —Hormonal cycle correlations
- —POTS — autonomic testing, tilt table findings
- —hEDS — Beighton, 2017 criteria
- —GI dysmotility — gastroparesis, SIBO
- —Small fiber neuropathy
- —Autoimmune features — ANA, thyroid antibodies
The Ternary Health approach to MCAS.
Review symptom pattern against both major diagnostic frameworks. Assess what testing has been done, what's been done correctly, and what's still missing.
Integrate the case with co-occurring conditions — POTS, hEDS, GI dysmotility, autoimmune features — rather than treating mast-cell symptoms in isolation.
Map the treatment landscape — the H1/H2 framework, mediator-specific agents, stabilizers, low-dose naltrexone, trigger management — with evidence grading per strategy.
Identify MCAS-aware specialists. Frame expectations about wait times, testing prep, and what to bring to each first visit.
How a MCAS case moves through our workflow.
Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.
What you receive.
- —A written case synthesis against the main diagnostic frameworks
- —Integration with co-occurring conditions (POTS, hEDS, GI, autoimmune)
- —Evidence-graded treatment-option map
- —A trigger and environment audit framework
- —Specialist identification with MCAS-specific experience
- —A written action plan and follow-up support as you implement it
What prospective MCAS clients ask most.
Ready for a case review?
Applications are reviewed within three business days.